StockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV)

Equities researchers at StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report issued on Saturday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and issued a $5.00 price target on shares of Minerva Neurosciences in a research report on Wednesday, November 6th.

Minerva Neurosciences Price Performance

NASDAQ NERV opened at $2.26 on Friday. The business has a 50 day moving average price of $2.28 and a 200 day moving average price of $2.70. The company has a market capitalization of $15.80 million, a P/E ratio of -5.14 and a beta of 0.11. Minerva Neurosciences has a 1-year low of $2.06 and a 1-year high of $13.49.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.